Best Neurology Companies in Switzerland
The 63 best Neurology companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MindMaze Therapeutics.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Switzerland
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MindMaze Therapeutics Developer of neurotherapeutic solutions combining behavior, software, devices, and data | $361M | 1 mo ago | Public | Tej Tadi Founder & Co-CEO | — | — | — | — |
| 2 | MindMaze 🦄 Digital neurotherapeutic platform for digital assessments and therapeutics | $224M | 52 mo ago | Series B | Tej Tadi Founder & CEO | 75 | — | 36 patents AI-driven neurorehabilitation devices for hand therapy, facial expression analysis, and SLAM tracking | 1 partnership · 2 expansions |
| 3 | Arvelle Therapeutics Developer of small molecule therapies for the treatment of CNS disorders | $223M | 73 mo ago | Acquired | — | 60 | — | — | — |
| 4 | Neurimmune Developer of antibody therapeutics for the treatment neurodegenerative diseases | $180M | 53 mo ago | Series B | Roger Nitsch CEO & President | 82 | — | 95 patents Antibody therapeutics and diagnostics targeting transthyretin amyloidosis and musculoskeletal diseases | — |
| 5 | Noema Pharma Developer of therapeutic solutions for treating neurological disorders | $172M | 18 mo ago | Series B | George Garibaldi President and Co-founder - head of Research and Development. | 21 | — | 80 patents PDE10 inhibitor therapeutics for CNS disorders, weight loss, and menopause treatments | — |
| 6 | Santhera Developer of drugs for treating mitochondrial and neuromuscular diseases | $159M | 39 mo ago | Public | — | 73 | 13 signals Contracts · Leadership · Funding | — | 1 award |
| 7 | Asceneuron Developer of small molecules for the treatment of neurodegenerative diseases | $137M | 23 mo ago | Series C | — | 3 | — | 159 patents Sulfoximine and piperazine-based glycosidase inhibitor compounds for therapeutic use | — |
| 8 | AC Immune Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative… | $120M | 29 mo ago | Public | Andrea Pfeifer CEO | 156 | 8 signals ▲60% Earnings · Layoffs · Leadership | 1,305 patents Patents concentrated in chemistry & materials | — |
| 9 | Synosia Therapeutics Developer of therapeutics for the treatment of CNS disorders | $91M | 188 mo ago | Acquired | — | 17 | — | — | — |
| 10 | Addex Therapeutics Developer of oral small molecules for neurological disorders | $71M | 33 mo ago | Public | Tim Dyer CEO | 24 | — | — | — |
| 11 | Neurosterix Developer of allosteric modulator therapeutics for neurological disorders | $63M | 26 mo ago | Series A | Tim Dyer CEO | — | — | — | — |
| 12 | Aleva Neuro Develops implantable deep brain stimulation systems that enables therapies for neurological diseases | $57M | 54 mo ago | Series E | Claudio Pollo Co-Founder | 30 | — | — | — |
| 13 | Prexton Therapeutics Parkinson’s drugs that target the metabotropic glutamate receptors. | $43M | 112 mo ago | Acquired | — | 5 | — | 68 patents Brain-penetrant chromone oxime allosteric modulators of metabotropic glutamate receptors for dyskinesia therapy | — |
| 14 | GeNeuro Developer of humanized monoclonal antibody for treating multiple sclerosis | $39M | 28 mo ago | Public | — | 20 | 4 signals ▼20% Lawsuit | 170 patents Therapeutic antibodies and compounds targeting HERV envelope proteins for disease treatment | — |
| 15 | Mabylon Developer of therapeutics for allergies and neurodegenerative diseases | $39M | 10 mo ago | Series B | Alcide Barberis CEO | — | — | 38 patents Therapeutic antibodies targeting allergens and ASC inflammasome proteins for allergy and inflammation treatment. | — |
| 16 | Vandria Developer of in-vitro screening platform for drug discovery and development | $31M | 22 mo ago | Series A | Patrick Aebischer Co-Founder | 6 | — | 38 patents Neuroprotective small‑molecule therapeutics using urolithin derivatives for ALS treatment | — |
| 17 | Synendos Therapeutics Developer of endocannabinoid modulators for the treatment of CNS disorders | $26M | 62 mo ago | Series A | Jurg Gertsch Co-Founder | 9 | — | — | 1 job opening |
| 18 | Monarch Bioimplants Developer of bioimplant for peripheral nerve repair | $25M | 68 mo ago | Series B | Thomas Freier Founder | — | — | 6 patents Chitosan-based implants for tissue support and urinary/sexual function post‑prostatectomy | — |
| 19 | NLS Pharma Developer of small molecule therapeutics for CNS, mental and behavioral disorders | $24M | 11 mo ago | Public | Eric Jean Desbois NLS Pharmaceutics Co-founder | 250 | 3 signals ▼80% M&A | 26 patents Controlled-release mazindol tablets for ADHD treatment | — |
| 20 | STALICLA Manufacturer of precision medicinea for neurodevelopmental disorders | $22M | 11 mo ago | Series B | Lynn Durham Founder & CEO | 26 | — | 116 patents Autism spectrum disorder diagnostics, biomarkers, and therapeutic pharmaceutical formulations. | — |
| 21 | Versameb Developer of therapies using proprietary technology platform for local delivery of therapeutic proteins | $13M | 71 mo ago | Seed | Klaas Zuideveld Chief Executive Officer | 16 | — | 74 patents RNA‑based therapeutics and modulators of protein interactions and gene expression | — |
| 22 | Somagenetix Developer of gene therapies to treat inherited immune diseases | $12M | 20 mo ago | Series A | Janine Reichenbach Co-Founder | 3 | — | — | — |
| 23 | NovaGo Therapeutics Company developing human derived antibodies for cerebral stroke and spinal cord injury | $10M | 87 mo ago | Series A | Martin Schwab Founder & President | 5 | — | 14 patents Therapeutic anti‑Nogo‑A antibodies for CNS injury and neuro‑degenerative disease treatment | — |
| 24 | Artiria Developer of micro-navigation system for stroke surgery | $9M | 27 mo ago | Series A | Marc Boers Co-Founder & COO | 12 | — | — | 1 award |
| 25 | Glia Pharm Developer of treatments for neurological and psychiatric disorders | $6M | 30 mo ago | Series A | — | 9 | — | — | — |
| 26 | machineMD Developer of a device for the diagnosis of brain disease | $5M | 15 mo ago | Seed | — | 16 | — | 9 patents Patents concentrated in health & consumer products | — |
| 27 | Release Tx Developer of encapsulated cell therapy device for the treatment of CNS diseases | $4M | 22 mo ago | Seed | Thomas Mehrling CEO | — | — | — | — |
| 28 | Rhovica Developer of an external ventricular drain to decrease intracranial pressure | $3M | 10 mo ago | Seed | Martin Hlavica Co-Founder | — | — | — | — |
| 29 | Gondola Medical Technologies Developer of a medical device for neurodegenerative disorders | $3M | 53 mo ago | Funding Raised | — | 15 | — | 7 patents Patents concentrated in health & consumer products | — |
| 30 | Deep Breath Intelligence Developer of AI and mass spectrometry-based platform for personalized medicine | $3M | 47 mo ago | Seed | Guillermo Vidal-De-Miguel Co-Founder | 10 | — | 3 patents Advanced high‑pressure gas storage systems for industrial and energy applications | — |
| 31 | Laevoroc Oncology Developer of therapeutics for cancer | $1M | 61 mo ago | Seed | Thomas Mehrling Founder-CEO at Laevoroc | 4 | — | — | — |
| 32 | Ability Switzerland A gait trainer for patients with neurological disorders | $288K | 189 mo ago | Seed | Simon Reich Co-Founder | — | — | — | — |
| 33 | Neurosoft Bioelectronics Provider of soft implantable electrodes for neurological disorders | $208K | 1 mo ago | Seed | Nicolas Vachicouras Co-Founder & CEO | 7 | — | — | 1 award |
| 34 | Translation-X Developer of therapeutics to treat Autism Spectrum Disorders | $177K | 20 mo ago | Seed | Ozgur Genc Founder | — | — | — | — |
| 35 | Clee Medical Developer of neurosurgical tools and techniques | $170K | 3 mo ago | Seed | Matthew Lapinski Co-Founder & CEO | — | — | — | — |
| 36 | OxyPrem Developer of a brain oxymetric device | $131K | 75 mo ago | Seed | Alexander Nitsch Co-Founder | 15 | — | — | — |
| 37 | ABCDx Provider of bio-markers for prognosis and diagnosis of brain injuries | $119K | 48 mo ago | Seed | Joan Montaner Co-Founder | 8 | — | 4 patents Biomarker assays for traumatic brain injury and large vessel occlusion diagnostics | 1 partnership · 1 award |
| 38 | Metys Pharmaceuticals Developer of drugs for chemotherapy-induced peripheral neuropathy | $113K | 85 mo ago | Acquired | Michael Scherz Founder & CEO | 10 | — | 69 patents Enantiomerically enriched neuroactive small molecules for CNS therapeutics | — |
| 39 | ND BioSciences Developer of therapeutics for neurodegenerative diseases | $109K | 44 mo ago | Seed | Hilal Lashuel Co-Founder & CSO | — | — | 5 patents Patents concentrated in health & consumer products | — |
Top 12 Neurology companies in Switzerland
#1
Public · Lausanne, Vaud · founded 2012$360.6Mraised▾
Developer of neurotherapeutic solutions combining behavior, software, devices, and data. The company offers a platform for brain health and recovery. It provides precision neurotherapeutics through a portfolio of solutions. The company also develops formulations for rare diseases. Its offerings include an immersive experience platform for brain recovery and a neurorehabilitation system. It provides a hand training peripheral and technology for digital motion assessments.
- Feb 2022Series B$105M
- Feb 2022Grant (prize money)$12.1M
- Oct 2021Conventional Debt$125M
- Sep 2017Angel—
#2
Series B · Schlieren, Zurich · founded 2015$38.7Mraised▾
Developer of therapeutics for allergies and neurodegenerative diseases. It offers antibody therapies for Peanut allergy, pollen allergy, ALS, neuroinflammation, and Alzheimer's disease.
- Aug 2025Series B$37M
- Sep 2024Grant (prize money)$1.5M
- May 2020Grant (prize money)$55.5K
- Dec 2019Grant (prize money)$55.1K
#3
Series B · Zurich, Zurich · founded 2019 · 21 employees$172Mraised▾
Developer of therapeutic solutions for treating neurological disorders. The company has developed NOE-101 mGluR5 NAM that acts as a negative allosteric modulator of mGlu5 receptors for the treatment of seizures associated with tuberous sclerosis complex and for the management of pain associated with Trigeminal Neuralgia. It also provides NOE-105 PDE 10Ai for the treatment of Tourette syndrome, NOE-109 mGluR2/3 NAM, NOE-115 TRI, and others.
- Dec 2024Series B$35M
- Mar 2023Series B$112M
- Dec 2020Series A$60M
- 2019Seed—
#4
Public · Stansstad, Nidwalden · founded 2015 · 250 employees$24.2Mraised▾
Developer of small molecule therapeutics for CNS, mental and behavioral disorders. The company's product line include NLS-1, mazindol, indicated for ADHD. The other therapeutic areas it is focusing on are Excessive Daytime Sleepiness, Pervasive Developmental Disorders, Iron Cerebral Insufficency, Cognitive Impairments, Synucleopathies, and Primary Insomnia.
- Jun 2025Post IPO$1M
- Mar 2025Post IPO$3M
- Jan 2025Post IPO$500K
- Oct 2024Post IPO$7.2M
#5
Series B · Geneva, Geneva · founded 2017 · 26 employees$21.6Mraised▾
Manufacturer of precision medicinea for neurodevelopmental disorders. It uses DEPI technology platform to develop pipeline candidate STP7 a multifaceted mGluR5 NAM pipeline to for cocaine abuse and other neurological indications.
- Jun 2025Series B$2.5M
- Jan 2024Conventional Debt$3.8M
- Jan 2024Series B$13.6M
- Jul 2022Grant (prize money)$1.7M
#6
Series C · Lausanne, Vaud · founded 2012 · 3 employees$137Mraised▾
Developer of small molecules for the treatment of neurodegenerative diseases. The company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease.
- Jul 2024Series C$100M
- May 2022Grant (prize money)—
- Oct 2016Grant (prize money)—
- Sep 2015Series A$30.6M
#7
Seed · Geneva, Geneva · founded 2019 · 7 employees$208.4Kraised▾
Provider of soft implantable electrodes for neurological disorders. The company offers its proprietary technology SOFT ECoG which is a subdural electrode made up of thin metal films of sub-micron thickness to achieve long-term bio-integration in the body, conforming to the static and dynamic mechanics of neural tissue. The company claims that the product is still under development and is not approved for human use.
- May 2026Seed$7.5M
- Mar 2023Grant (prize money)$38.4K
- Apr 2022Grant (prize money)—
- Apr 2022Seed$100K
#8
Seed · Bern, Canton of Bern · founded 2021$3.1Mraised▾
Developer of an external ventricular drain to decrease intracranial pressure. The company develops products that are thin catheters that are inserted into brain cavities (ventricles) to measure intracranial pressure and drain fluid to decrease it.
- Aug 2025Seed$2.9M
- Dec 2022Grant (prize money)$161.1K
#9
Series A · Lausanne, Vaud · founded 2018 · 6 employees$30.7Mraised▾
Developer of in-vitro screening platform for drug discovery and development. The company has created a platform for identifying and discovering small compounds (mitophagy inducers). It aids in the identification of the leading candidate molecule linked to age-related and chronic diseases.
- Aug 2024Series A—
- Dec 2023Series A$20.6M
#10
Public · Lausanne, Vaud · founded 2003 · 156 employees$119.8Mraised▾
Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases. It has a diversified pipeline of drugs for Alzheimer’s disease, Parkinson’s, Down syndrome, and Glaucoma. The company has technology platforms, SupraAntigen and Morphomer which generate sensitive diagnostics, highly specific biologics and small molecule drugs.
- Dec 2023Post IPO—
- Sep 2022Grant (prize money)$500K
- Sep 2019Grant (prize money)—
- Dec 2018Post IPO$50M
#11
Seed · Bern, Canton of Bern · founded 2019 · 16 employees$4.8Mraised▾
Developer of a device for the diagnosis of brain disease. It offers NeurOphthalmoscope a diagnostic device for an automated, objective, and quantifiable analysis of brain functions related to the visual system.
- Mar 2025Seed—
- Sep 2022Seed$3.3M
- Dec 2021Seed$1.5M
#12
Series A · Zurich, Zurich · founded 2018 · 3 employees$11.7Mraised▾
Developer of gene therapies to treat inherited immune diseases. Through genetically modified phagocytes, the company uses proprietary technologies to deliver ex-vivo gene treatments to patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastasis.
- Oct 2024Series A$11.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Switzerland
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 648 Switzerland-affiliated papers.
- ETH Zurich102
- École Polytechnique Fédérale de Lausanne96
- University Hospital of Bern85
- University of Zurich73
- University Hospital of Zurich64
- Deep brain stimulation8→25
- Stimulation3→19
- Physical medicine and rehabilitation4→12
- Neuromodulation2→10
- Neuroprosthetics13→20
- Deep brain stimulation37→100
- Subthalamic nucleus22→51
- Parkinson's disease11→40
- Stimulation24→50
- Neurostimulation6→22
- Neurostimulation2→8
- Sensory system1→6
- Neuroprosthetics1→6
- Cognition2→4
- Subthalamic nucleus11→13
Where neurotech is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.